4.485
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Maia Biotechnology Inc | MAIA | AMEX | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 4.485 | 04:01:06 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.485 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 3.10 - 9.64 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 4.485 | USD |
Period:
Draw Mode:
Maia Biotechnology Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 49.09M | 10.95M | 7.52M | $ - | $ - | -1.18 | -3.10 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 24.03k | 25.60% |
Maia Biotechnology News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MAIA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.74 | 4.7797 | 4.18 | 4.38 | 16,620 | -0.255 | -5.38% |
| 1 Month | 3.55 | 4.89 | 3.37 | 4.21 | 28,174 | 0.935 | 26.34% |
| 3 Months | 3.84 | 4.89 | 3.25 | 3.87 | 17,872 | 0.645 | 16.8% |
| 6 Months | 7.00 | 9.64 | 3.10 | 5.99 | 241,070 | -2.52 | -35.93% |
| 1 Year | 4.10 | 9.64 | 3.10 | 5.92 | 292,338 | 0.385 | 9.39% |
| 3 Years | 4.10 | 9.64 | 3.10 | 5.92 | 292,338 | 0.385 | 9.39% |
| 5 Years | 4.10 | 9.64 | 3.10 | 5.92 | 292,338 | 0.385 | 9.39% |
Maia Biotechnology Description
| MAIA Biotechnology Inc is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells. |